ascopubs.org

A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...
ascopubs.org

Risk of pre-cancerous advanced adenomas of the colon in long distance runners.

The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.
ascopubs.org

A Breast Cancer Hub initiative, conducting door-to-door cervical cancer awareness, symptom identification in 11,277 women, and providing screening and treatment support in ...

Training an alternate oncology workforce: Attendee feedback. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
ascopubs.org

Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with ...

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
ascopubs.org

Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II. This abstract does not ...
ascopubs.org

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non ...

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA ...